Meta-analysis of effectiveness and safety of levfloxacin and other drugs in treatment of patients with lower respiratory tract infections

Abstract

Abstract: AIM: To explore the difference of efficacy and safety between levfloxacin and other drugs in treatment of patients with lower respiratory tract infections. METHODS: The efficacies and safety of levfloxacin or other drugs in treating lower respiratory tract infections were analyzed by Meta-analysis in homogeneity test and combined test in 16 studies. RESULTS: Homogeneity test showed that the cited studies of efficacy and safety were homogeneous with χ² =15.8844, χ² =2.2231, P > 0.05.In combined test, the combined OR = 2.1885, OR_合并=0.9516 and its 95 % confidence interval was in 1.6044 -2.9853 and 0.5958 -1.5199, respectively. CONCLUSION: The effectiveness of levfloxacin in treating lower respiratory tract infections is significantly superior to those of the medications used at present. The rate of bacterial clearance was high and the rate of side effects was low.

Key words: Meta-analysis, lower respiratory tract infections, levfloxacin, efficacy, safety

CLC Number:

R969.4

LIU Hong-xia, ZHENG Qing-shan. Meta-analysis of effectiveness and safety of levfloxacin and other drugs in treatment of patients with lower respiratory tract infections[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(7): 795-798.

References

1 韦秀平, 王素秋.左氧氟沙星与头孢曲松治疗老年细菌性下呼吸道感染临床分析[J]. 中国抗生素杂志, 2000;25: 158-60
2 李家辉, 张华芬, 伏长贵.左氧氟沙星与环丙沙星治疗老年人下呼吸道感染61例随机对照观察[J]. 中国抗感染化疗杂志, 2002; 2:37-8
3 程德云, 唐晓燕, 陈文彬.左氧氟沙星和头孢克罗治疗慢性阻塞性肺病下呼吸道感染的对比观察[J]. 四川医学,2000;21: 481-3
4 赵清齐, 武红.左氧氟沙星治疗下呼吸道感染对比观察[J]. 新乡医学院学报, 2002;19:407-8
5 徐惠, 王作梅.乳酸左氧氟沙星与头孢哌酮舒巴坦对照治疗老年人下呼吸道感染的临床研究[J]. 中国抗生素杂志, 1999;24:19-20
6 黄学锐, 杜亚东, 高薇薇.乳酸左氧氟沙星与头孢噻肟钠治疗肺结核合并下呼吸道感染64 例临床分析[J]. 中国抗生素杂志, 1999;24: 32-5
7 张树才, 袁辉, 杨新杰.乳酸左氧氟沙星与头孢呋辛钠治疗下呼吸道感染临床对照观察[J]. 中国抗生素杂志,1999;24:312-4
8 廖美艳, 肖玉梅.左氧氟沙星治疗老年下呼吸道感染38例临床分析[J]. 广州医药, 2001; 32:26-7
9 殷振勇.左氧氟沙星胶囊治疗下呼吸道感染疗效观察[J]. 中国临床药学杂志, 2001; 10:388-9
10 徐乃明.左氧氟沙星与头孢哌酮治疗下呼吸道感染的疗效观察[J]. 山西医药杂志, 2000; 29:429-30
11 刘孟兴袁玉红.左氧氟沙星治疗下呼吸道感染临床观察[J]. 医学论坛杂志, 2004; 25:55
12 王汝更, 贺凤义, 马振芬.左氧氟沙星治疗下呼吸道感染临床观察[J]. 济宁医学院学报, 2003;26: 57
13 彭单云.左氧氟沙星治疗下呼吸道感染临床疗效评价[J]. 贵州医药. 2005; 29:42-3
14 林桥文.左氧氟沙星治疗下呼吸道感染的疗效观察[J]. 医学理论与实践, 2005;18: 396-7
15 赵菊萍, 王积良, 刘立平.左氧氟沙星治疗下呼吸道感染64 例临床及病原学分析[J]. 陕西医学杂志, 2003; 32: 583-6
16 王曦, 孟巍, 侯大平.乳酸左氧氟沙星治疗下呼吸道感染120 例的临床疗效分析[J]. 黑龙江医药科学, 2004;27:73-4
17 富振英.Meta -Analysis 研究资料的统计分析方法[J]. 药物流行病学杂志, 1994;3: 220-2
18 刘关键, 王家良, 康德英, 四格表数据Meta 分析的简明统计方法[J].华西医科大学学报, 2000;31: 265-8

[1]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[2]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[3]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[4]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[5]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[6]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[7]	YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong. Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990.
[8]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[9]	YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong. Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
[10]	BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong. Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
[11]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[12]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[13]	YU Zhaolei, BAI Jianling, YU Hao, ZHAO Yang. Development of tools for clinical trial information retrieval and Meta-analysis based on R-Shiny: Taking non-small cell lung cancer as an example [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 984-991.
[14]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
[15]	CHEN Wenjun, RUAN Zourong, XIANG Xiaoqiang. Development and application progress of physiologically based pharmacokinetic modeling and its combined use with other modeling methods [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 299-305.